IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

Multiple myeloma (MM) patients who receive killer cell Ig–like receptor (KIR) ligand–mismatched, T cell–depleted, allogeneic transplantation may have a reduced risk of relapse compared with patients who receive KIR ligand–matched grafts, suggesting the importance of this signaling axis in the natura...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Benson, Don M., Bakan, Courtney E., Zhang, Shuhong, Collins, Shauna M., Liang, Jing, Srivastava, Shivani, Hofmeister, Craig C., Efebera, Yvonne, Andre, Pascale, Romagne, Francois, Bléry, Mathieu, Bonnafous, Cécile, Zhang, Jianying, Clever, David, Caligiuri, Michael A., Farag, Sherif S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2011
Assuntos:
Immunobiology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3490103/
https://ncbi.nlm.nih.gov/pubmed/22031859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-06-360255
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados